Heart failure & cardiomyopathies
The Interaction Between Physical Frailty and Prognostic Impact of Heart Failure Medication in Elderly Patients
Authors' conclusion
The presence of physical frailty did not interact with the beneficial prognostic impact of RAASi and beta-blocker combination therapy in elderly patients with HFr/mrEF.
Study context
- Population
- Hospitalised heart failure (HF) patients aged ≥65 years with LVEF <50% (HFr/mrEF); physical frailty = ≥3 items on the Japanese version of the Cardiovascular Health Study criteria604 [59%] physically frail
- Participants
- 1,021 patients
- Exposure
- Renin-angiotensin-aldosterone system inhibitors (RAASi) and beta-blockers at discharge vs neither, by physical frailty
- RAASi and beta-blockersn = 604
- Outcome
- All-cause mortality rate
Methodological detailscombined FRAGILE-HF and Kitasato cohorts, covariate-adjusted
- Combined FRAGILE-HF and Kitasato cohorts
- Covariate-adjusted
Main finding
As reported in the abstract
1-year mortality
RAASi + beta-blockers vs NeitherHazard ratio (95% CI)
Adjusted; all patients
0.50(0.34–0.75)
HR
- Physically frail
- 0.53
- Not physically frail
- 0.51
Observational data: associations, not effects.
Original publication
The Interaction Between Physical Frailty and Prognostic Impact of Heart Failure Medication in Elderly Patients. ESC Heart Fail. Published 23 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →